Varicella zoster virus infection in inflammatory bowel disease

Inflammatory Bowel Diseases

Volumn 18, Issue 12, 2012, Pages 2392-2403

  Cullen, Garret ^a,b   Baden, Rachel P ^a,b   Cheifetz, Adam S ^a,b  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

immunosuppressed; inflammatory bowel disease; Varicella zoster virus; viral infection

Indexed keywords

ACICLOVIR; ADALIMUMAB; AZATHIOPRINE; CERTOLIZUMAB PEGOL; ETANERCEPT; IMMUNOGLOBULIN; IMMUNOGLOBULIN G; INFLIXIMAB; MERCAPTOPURINE; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NATALIZUMAB; PLACEBO; STEROID; TACROLIMUS; VALACICLOVIR;

CASE CONTROL STUDY; CROHN DISEASE; DISSEMINATED INTRAVASCULAR CLOTTING; ENTERITIS; HEALTH CARE PERSONNEL; HEALTH INSURANCE; HERPES ZOSTER; HUMAN; IMMUNOCOMPROMISED PATIENT; MATERNAL MORBIDITY; PASSIVE IMMUNIZATION; POSTHERPETIC NEURALGIA; PRIMARY INFECTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; REVIEW; RHEUMATOID ARTHRITIS; RISK; ULCERATIVE COLITIS; VARICELLA ZOSTER VIRUS; VIRUS REACTIVATION;

ADOLESCENT; ADULT; CHICKENPOX; CHILD; FEMALE; HERPES ZOSTER; HERPESVIRUS 3, HUMAN; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFLAMMATORY BOWEL DISEASES; MALE; RISK FACTORS; YOUNG ADULT;

EID: 84869229513     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1002/ibd.22950     Document Type: Review

References (92)

1. Salliot C, Gossec L, Ruyssen-Witrand A, et al. Infections during tumour necrosis factor-alpha blocker therapy for rheumatic diseases in daily practice: a systematic retrospective study of 709 patients. Rheumatology (Oxford). 2007; 46: 327-334.
2. Arvin AM,. Varicella-zoster virus. Clin Microbiol Rev. 1996; 9: 361-381.
3. Ooi PL, Goh KT, Doraisingham S, et al. Prevalence of varicella-zoster virus infection in Singapore. Southeast Asian J Trop Med Public Health. 1992; 23: 22-25.
4. Colombel JF, Loftus EV Jr, Tremaine WJ, et al. The safety profile of infliximab in patients with Crohn's disease: the Mayo clinic experience in 500 patients. Gastroenterology. 2004; 126: 19-31.
5. Fidder H, Schnitzler F, Ferrante M, et al. Long-term safety of infliximab for the treatment of inflammatory bowel disease: a single-centre cohort study. Gut. 2009; 58: 501-508.
6. Gupta G, Lautenbach E, Lewis JD,. Incidence and risk factors for herpes zoster among patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2006; 4: 1483-1490.
7. Marehbian J, Arrighi HM, Hass S, et al. Adverse events associated with common therapy regimens for moderate-to-severe Crohn's disease. Am J Gastroenterol. 2009; 104: 2524-2533.
8. Grose C,. Variation on a theme by Fenner: the pathogenesis of chickenpox. Pediatrics. 1981; 68: 735-737.
9. Gold E,. Serologic and virus-isolation studies of patients with varicella or herpes-zoster infection. N Engl J Med. 1966; 274: 181-185.
10. Davison AJ, Scott JE,. The complete DNA sequence of varicella-zoster virus. J Gen Virol. 1986; 67 (Pt 9): 1759-1816.
11. Sauerbrei A, Philipps A, Zell R, et al. Genotyping of varicella-zoster virus strains after serial passages in cell culture. J Virol Methods. 2007; 145: 80-83.
12. Nikkels AF, Delvenne P, Sadzot-Delvaux C, et al. Distribution of varicella zoster virus and herpes simplex virus in disseminated fatal infections. J Clin Pathol. 1996; 49: 243-248.
13. Torigo S, Ihara T, Kamiya H,. IL-12, IFN-gamma, and TNF-alpha released from mononuclear cells inhibit the spread of varicella-zoster virus at an early stage of varicella. Microbiol Immunol. 2000; 44: 1027-1031.
14. Boussault P, Boralevi F, Labbe L, et al. Chronic varicella-zoster skin infection complicating the congenital varicella syndrome. Pediatr Dermatol. 2007; 24: 429-432.
15. Prober CG, Gershon AA, Grose C, et al. Consensus: varicella-zoster infections in pregnancy and the perinatal period. Pediatr Infect Dis J. 1990; 9: 865-869.
16. Keene JK, Lowe DK, Grosfeld JL, et al. Disseminated varicella complicating ulcerative colitis. JAMA. 1978; 239: 45-46.
17. Leung VS, Nguyen MT, Bush TM,. Disseminated primary varicella after initiation of infliximab for Crohn's disease. Am J Gastroenterol. 2004; 99: 2503-2504.
18. Springfeld C, Sauerbrei A, Filusch A, et al. Fatal varicella in an immunocompromised adult associated with a European genotype E2 variant of varicella zoster virus. J Clin Virol. 2009; 44: 70-73.
19. Deutsch DE, Olson AD, Kraker S, et al. Overwhelming varicella pneumonia in a patient with Crohn's disease treated with 6-mercaptopurine. J Pediatr Gastroenterol Nutr. 1995; 20: 351-353.
20. Nagel MA, Gilden DH,. The protean neurologic manifestations of varicella-zoster virus infection. Cleve Clin J Med. 2007; 74: 489-494.
21. Yawn BP, Saddier P, Wollan PC, et al. A population-based study of the incidence and complication rates of herpes zoster before zoster vaccine introduction. Mayo Clin Proc. 2007; 82: 1341-1349.
22. Hambleton S, Gershon AA,. Preventing varicella-zoster disease. Clin Microbiol Rev. 2005; 18: 70-80.
23. Cullen G, Krakower D, Mitty JA, et al. Varicella zoster meningoradiculitis in Crohn's disease treated with 6-mercaptopurine. Inflamm Bowel Dis. 2011; 17: E109-110.
24. Dueland AN, Devlin M, Martin JR, et al. Fatal varicella-zoster virus meningoradiculitis without skin involvement. Ann Neurol. 1991; 29: 569-572.
25. Wendling D, Streit G, Toussirot E, et al. Herpes zoster in patients taking TNFalpha antagonists for chronic inflammatory joint disease. Joint Bone Spine. 2008; 75: 540-543.
26. Toruner M, Loftus EV Jr, Harmsen WS, et al. Risk factors for opportunistic infections in patients with inflammatory bowel disease. Gastroenterology. 2008; 134: 929-936.
27. Colombel JF, Sandborn WJ, Reinisch W, et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med. 2010; 362: 1383-1395.
28. Lichtenstein GR, Feagan BG, Cohen RD, et al. Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry. Clin Gastroenterol Hepatol. 2006; 4: 621-630.
29. Herrero JI, Quiroga J, Sangro B, et al. Herpes zoster after liver transplantation: incidence, risk factors, and complications. Liver Transpl. 2004; 10: 1140-1143.
30. Borba EF, Ribeiro AC, Martin P, et al. Incidence, risk factors, and outcome of Herpes zoster in systemic lupus erythematosus. J Clin Rheumatol. 2010; 16: 119-122.
31. Antonelli MA, Moreland LW, Brick JE,. Herpes zoster in patients with rheumatoid arthritis treated with weekly, low-dose methotrexate. Am J Med. 1991; 90: 295-298.
32. Salliot C, van der Heijde D,. Long-term safety of methotrexate monotherapy in patients with rheumatoid arthritis: a systematic literature research. Ann Rheum Dis. 2009; 68: 1100-1104.
33. Wong GH, Goeddel DV,. Tumour necrosis factors alpha and beta inhibit virus replication and synergize with interferons. Nature. 1986; 323: 819-822.
34. Ricart E, Panaccione R, Loftus EV, et al. Infliximab for Crohn's disease in clinical practice at the Mayo Clinic: the first 100 patients. Am J Gastroenterol. 2001; 96: 722-729.
35. Farrell RJ, Shah SA, Lodhavia PJ, et al. Clinical experience with infliximab therapy in 100 patients with Crohn's disease. Am J Gastroenterol. 2000; 95: 3490-3497.
36. Strangfeld A, Listing J, Herzer P, et al. Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-alpha agents. JAMA. 2009; 301: 737-744.
37. Glesby MJ, Moore RD, Chaisson RE,. Clinical spectrum of herpes zoster in adults infected with human immunodeficiency virus. Clin Infect Dis. 1995; 21: 370-375.
38. Veenstra J, Krol A, van Praag RM, et al. Herpes zoster, immunological deterioration and disease progression in HIV-1 infection. AIDS. 1995; 9: 1153-1158.
39. Manuel O, Kumar D, Singer LG, et al. Incidence and clinical characteristics of herpes zoster after lung transplantation. J Heart Lung Transplant. 2008; 27: 11-16.
40. Arness T, Pedersen R, Dierkhising R, et al. Varicella zoster virus-associated disease in adult kidney transplant recipients: incidence and risk-factor analysis. Transpl Infect Dis. 2008; 10: 260-268.
41. Whitley RJ, Gnann JW Jr,. Herpes zoster in the age of focused immunosuppressive therapy. JAMA. 2009; 301: 774-775.
42. Salmon-Ceron D, Tubach F, Lortholary O, et al. Drug-specific risk of non-tuberculosis opportunistic infections in patients receiving anti-TNF therapy reported to the 3-year prospective French RATIO registry. Ann Rheum Dis. 2011; 70: 616-623.
43. Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet. 2002; 359: 1541-1549.
44. Sands BE, Anderson FH, Bernstein CN, et al. Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med. 2004; 350: 876-885.
45. Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005; 353: 2462-2476.
46. Colombel JF, Sandborn WJ, Rutgeerts P, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology. 2007; 132: 52-65.
47. Schreiber S, Khaliq-Kareemi M, Lawrance IC, et al. Maintenance therapy with certolizumab pegol for Crohn's disease. N Engl J Med. 2007; 357: 239-250.
48. Sandborn WJ, Colombel JF, Enns R, et al. Natalizumab induction and maintenance therapy for Crohn's disease. N Engl J Med. 2005; 353: 1912-1925.
49. Holmen C, Piehl F, Hillert J, et al. A Swedish national post-marketing surveillance study of natalizumab treatment in multiple sclerosis. Mult Scler. 2011; 17: 708-719.
50. Horl MP, Schmitz M, Ivens K, et al. Opportunistic infections after renal transplantation. Curr Opin Urol. 2002; 12: 115-123.
51. Present DH, Meltzer SJ, Krumholz MP, et al. 6-Mercaptopurine in the management of inflammatory bowel disease: short- and long-term toxicity. Ann Intern Med. 1989; 111: 641-649.
52. Shale MJ, Seow CH, Coffin CS, et al. Review article: chronic viral infection in the anti-tumour necrosis factor therapy era in inflammatory bowel disease. Aliment Pharmacol Ther. 2010; 31: 20-34.
53. Maranich AM, Rajnik M,. Varicella-specific immunoglobulin G titers in commercial intravenous immunoglobulin preparations. Pediatrics. 2009; 124: e484-488.
54. Sands BE, Cuffari C, Katz J, et al. Guidelines for immunizations in patients with inflammatory bowel disease. Inflamm Bowel Dis. 2004; 10: 677-692.
55. Marin M, Guris D, Chaves SS, et al. Prevention of varicella: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2007; 56: 1-40.
56. Helgason S, Petursson G, Gudmundsson S, et al. Prevalence of postherpetic neuralgia after a first episode of herpes zoster: prospective study with long term follow up. BMJ. 2000; 321: 794-796.
57. Gourishankar S, McDermid JC, Jhangri GS, et al. Herpes zoster infection following solid organ transplantation: incidence, risk factors and outcomes in the current immunosuppressive era. Am J Transplant. 2004; 4: 108-115.
58. Javed S, Kamili QU, Mendoza N, et al. Possible association of lower rate of postherpetic neuralgia in patients on anti-tumor necrosis factor-alpha. J Med Virol. 2011; 83: 2051-2055.
59. Melmed GY, Ippoliti AF, Papadakis KA, et al. Patients with inflammatory bowel disease are at risk for vaccine-preventable illnesses. Am J Gastroenterol. 2006; 101: 1834-1840.
60. Rahier JF, Yazdanpanah Y, Colombel JF, et al. The European (ECCO) Consensus on infection in IBD: what does it change for the clinician? Gut. 2009; 58: 1313-1315.
61. Gershon AA,. The current status of live attenuated varicella vaccine. Arch Virol Suppl. 2001; 17: 1-6.
62. Vazquez M, Shapiro ED,. Varicella vaccine and infection with varicella-zoster virus. N Engl J Med. 2005; 352: 439-440.
63. Sharrar RG, LaRussa P, Galea SA, et al. The postmarketing safety profile of varicella vaccine. Vaccine. 2000; 19: 916-923.
64. Davis MM, Patel MS, Gebremariam A,. Decline in varicella-related hospitalizations and expenditures for children and adults after introduction of varicella vaccine in the United States. Pediatrics. 2004; 114: 786-792.
65. Oxman MN, Levin MJ, Johnson GR, et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med. 2005; 352: 2271-2284.
66. Harpaz R, Ortega-Sanchez IR, Seward JF,. Prevention of herpes zoster: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2008; 57: 1-30.
67. Kotton CN,. Nailing down the shingles in IBD. Inflamm Bowel Dis. 2007; 13: 1178-1179.
68. Takahashi M, Kamiya H, Baba K, et al. Clinical experience with Oka live varicella vaccine in Japan. Postgrad Med J. 1985; 61 (Suppl 4): 61-67.
69. Arbeter AM, Granowetter L, Starr SE, et al. Immunization of children with acute lymphoblastic leukemia with live attenuated varicella vaccine without complete suspension of chemotherapy. Pediatrics. 1990; 85: 338-344.
70. Armenian SH, Han JY, Dunaway TM, et al. Safety and immunogenicity of live varicella virus vaccine in children with human immunodeficiency virus type 1. Pediatr Infect Dis J. 2006; 25: 368-370.
71. Kano H, Mizuta K, Sakakihara Y, et al. Efficacy and safety of immunization for pre- and post-liver transplant children. Transplantation. 2002; 74: 543-550.
72. Pileggi GS, de Souza CB, Ferriani VP,. Safety and immunogenicity of varicella vaccine in patients with juvenile rheumatic diseases receiving methotrexate and corticosteroids. Arthritis Care Res (Hoboken). 2010; 62: 1034-1039.
73. Lu Y, Bousvaros A,. Varicella vaccination in children with inflammatory bowel disease receiving immunosuppressive therapy. J Pediatr Gastroenterol Nutr. 2010; 50: 562-565.
74. Vickrey E, Allen S, Mehta J, et al. Acyclovir to prevent reactivation of varicella zoster virus (herpes zoster) in multiple myeloma patients receiving bortezomib therapy. Cancer. 2009; 115: 229-232.
75. Mouzas IA, Greenstein AJ, Giannadaki E, et al. Management of varicella infection during the course of inflammatory bowel disease. Am J Gastroenterol. 1997; 92: 1534-1537.
76. Vergara M, Brullet E, Campo R, et al. [Fulminant infection caused by varicella herpes zoster in patient with Crohn disease undergoing treatment with azathioprine.] Gastroenterol Hepatol. 2001; 24: 47.
77. Triantafillidis JK, Cheracakis P,. Severe infection by varicella virus in an adult with ulcerative colitis: favourable response to acyclovir treatment. Dig Liver Dis. 2002; 34: 383-384.
78. Lemyze M, Tavernier JY, Chevalon B, et al. [Severe varicella zoster pneumonia during the course of treatment with azathioprine for Crohn's disease.] Rev Mal Respir. 2003; 20: 773-776.
79. Bernal I, Domenech E, Garcia-Planella E, et al. [Opportunistic infections in patients with inflammatory bowel disease undergoing immunosuppressive therapy.] Gastroenterol Hepatol. 2003; 26: 19-22.
80. Tougeron D, Mauillon J, Tranvouez JL,. [Severe varicella infection during treatment with infliximab for Crohn's disease.] Gastroenterol Clin Biol. 2006; 30: 1410-1413.
81. Lawrance IC, Radford-Smith GL, Bampton PA, et al. Serious infections in patients with inflammatory bowel disease receiving anti-tumor-necrosis-factor- alpha therapy: an Australian and New Zealand experience. J Gastroenterol Hepatol. 2010; 25: 1732-1738.
82. Kunz AN, Rajnik M,. Disseminated cutaneous varicella zoster virus infections during infliximab therapy for Crohn's disease: case report of two pediatric patients at one institution. Clin Pediatr (Phila). 2011; 50: 559-561.
83. Korelitz BI, Fuller SR, Warman JI, et al. Shingles during the course of treatment with 6-mercaptopurine for inflammatory bowel disease. Am J Gastroenterol. 1999; 94: 424-426.
84. Kader HA, Mascarenhas MR, Piccoli DA, et al. Experiences with 6-mercaptopurine and azathioprine therapy in pediatric patients with severe ulcerative colitis. J Pediatr Gastroenterol Nutr. 1999; 28: 54-58.
85. Russell RK, Richardson N, Wilson DC,. Systemic absorption with complications during topical tacrolimus treatment for orofacial Crohn disease. J Pediatr Gastroenterol Nutr. 2001; 32: 207-208.
86. Baumgart DC, Dignass AU,. Shingles following infliximab infusion. Ann Rheum Dis. 2002; 61: 661.
87. Stephens MC, Shepanski MA, Mamula P, et al. Safety and steroid-sparing experience using infliximab for Crohn's disease at a pediatric inflammatory bowel disease center. Am J Gastroenterol. 2003; 98: 104-111.
88. Friesen CA, Calabro C, Christenson K, et al. Safety of infliximab treatment in pediatric patients with inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2004; 39: 265-269.
89. Shin BS, Seo HD, Na CH, et al. Case of herpes zoster duplex bilateralis. J Dermatol. 2009; 36: 95-97.
90. Govani SM, Higgins PD,. Combination of thiopurines and allopurinol: adverse events and clinical benefit in IBD. J Crohns Colitis. 2010; 4: 444-449.
91. Monaghan TM, Norton B,. Varicella pneumonia in an immunocompromised inflammatory bowel disease patient. Inflamm Bowel Dis. 2010; 16: 364-365.
92. Cruz MJ, Baudrier T, Ferreira O, et al. Herpes zoster at the site of infliximab infusion: case report. Cutan Ocul Toxicol. 2011; 30: 236-238.